CYNTHIA PIPPINS: Open Payments
NPI 1184073538 · MONROE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$720 in 36 payments from 19 companies in 2025. Trend: 2023 $477 · 2024 $833 · 2025 $720
Food & beverage: $720
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 9 | $143 |
| Supernus Pharmaceuticals, Inc. | 2 | $133 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $106 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Insulet Corporation | 1 | $20 |
| ABBVIE INC. | 1 | $19 |
| IBSA Pharma Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
Products named: Qelbree, CAPLYTA, OTEZLA, Kerendia, REPATHA, REXULTI, VPRIV, Omnipod.
Industry payments across LA — which companies pay providers there.
